BACKGROUND: A shorter duration of untreated psychosis in patients with schizophrenia results in better symptomatic and functional outcomes. Therefore, identifying biological markers in the early stages of psychosis is an important step toward early detection and intervention. Mismatch negativity (MMN) and P3a are leading candidate biomarkers. MMN measures differ in their sensitivity to varying deviants. However, this has not been fully addressed in assessing the early stages of psychosis. In the current study, we examined MMN/P3a to duration deviant (dMMN/dP3a) and frequency deviant (fMMN/fP3a) in the early stages of psychosis. To our knowledge, this is the first study that examined both MMN/P3a to duration deviant (dMMN/dP3a) and frequency deviant (fMMN/fP3a) in the early stages of psychosis. METHODS: Participants consisted of 20 patients with first episode schizophrenia (FES), 21 ultra-high risk (UHR) individuals, and 22 healthy controls (HC). We measured dMMN/dP3a and fMMN/fP3a ERP components by means of a 64 electrodes-cap for EEG recording, and we used two-tone auditory oddball paradigms with 2000 stimuli. RESULTS: The amplitude of dMMN was significantly reduced in FES and UHR compared to HC. The amplitude of fMMN showed no significant difference among the three groups. The amplitudes of dP3a and fP3a were significantly reduced in FES and UHR compared to HC. CONCLUSION: These findings suggest that dMMN may have higher sensitivity than fMMN whereas dP3a and fP3a may have similar sensitivity in the early stages of psychosis.
BACKGROUND: A shorter duration of untreated psychosis in patients with schizophrenia results in better symptomatic and functional outcomes. Therefore, identifying biological markers in the early stages of psychosis is an important step toward early detection and intervention. Mismatch negativity (MMN) and P3a are leading candidate biomarkers. MMN measures differ in their sensitivity to varying deviants. However, this has not been fully addressed in assessing the early stages of psychosis. In the current study, we examined MMN/P3a to duration deviant (dMMN/dP3a) and frequency deviant (fMMN/fP3a) in the early stages of psychosis. To our knowledge, this is the first study that examined both MMN/P3a to duration deviant (dMMN/dP3a) and frequency deviant (fMMN/fP3a) in the early stages of psychosis. METHODS:Participants consisted of 20 patients with first episode schizophrenia (FES), 21 ultra-high risk (UHR) individuals, and 22 healthy controls (HC). We measured dMMN/dP3a and fMMN/fP3a ERP components by means of a 64 electrodes-cap for EEG recording, and we used two-tone auditory oddball paradigms with 2000 stimuli. RESULTS: The amplitude of dMMN was significantly reduced in FES and UHR compared to HC. The amplitude of fMMN showed no significant difference among the three groups. The amplitudes of dP3a and fP3a were significantly reduced in FES and UHR compared to HC. CONCLUSION: These findings suggest that dMMN may have higher sensitivity than fMMN whereas dP3a and fP3a may have similar sensitivity in the early stages of psychosis.
Authors: Michael Avissar; Shanghong Xie; Blair Vail; Javier Lopez-Calderon; Yuanjia Wang; Daniel C Javitt Journal: Schizophr Res Date: 2017-07-11 Impact factor: 4.939
Authors: Dean F Salisbury; Nicola R Polizzotto; Paul G Nestor; Sarah M Haigh; Justine Koehler; Robert W McCarley Journal: Schizophr Bull Date: 2017-03-01 Impact factor: 9.306
Authors: Gregory A Light; Neal R Swerdlow; Michael L Thomas; Monica E Calkins; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Keith H Nuechterlein; Marlena Pela; Allen D Radant; Larry J Seidman; Richard F Sharp; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine A Sugar; Debby W Tsuang; Ming T Tsuang; David L Braff; Bruce I Turetsky Journal: Schizophr Res Date: 2014-10-23 Impact factor: 4.939
Authors: Stephanie Thiebes; Gregor Leicht; Stjepan Curic; Saskia Steinmann; Nenad Polomac; Christina Andreou; Iris Eichler; Lars Eichler; Christian Zöllner; Jürgen Gallinat; Ileana Hanganu-Opatz; Christoph Mulert Journal: J Psychiatry Neurosci Date: 2017-06 Impact factor: 6.186
Authors: Rachel A Hay; Brian J Roach; Vinod H Srihari; Scott W Woods; Judith M Ford; Daniel H Mathalon Journal: Biol Psychol Date: 2015-01-17 Impact factor: 3.251
Authors: Amanda McCleery; Daniel H Mathalon; Jonathan K Wynn; Brian J Roach; Gerhard S Hellemann; Stephen R Marder; Michael F Green Journal: Psychol Med Date: 2019-01-15 Impact factor: 7.723